RAF/MEK clamp inhibition with avutometinib and cetuximab in RAF1 S257L–mutated, anti-EGFR–refractory metastatic colorectal cancer in Gaucher’s disease
Open Access
- 19 August 2026
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (10)
Abstract
RAF1 alterations are rare in metastatic colorectal cancer (mCRC), occurring in roughly 0.5% of cases, and lack established treatment guidance. We present a patient with RAF1 S257L–mutated, RAS wild-type mCRC and concurrent type 1 Gaucher disease, whose baseline cytopenias precluded standard chemotherapy and clinical-trial enrollment. After progression on fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens (the latter with the anti-EGFR antibody panitumumab) complicated by recurrent neutropenic sepsis, he received off-label avutometinib and defactinib (an oral RAF/MEK clamp inhibitor plus a FAK inhibitor) combined with cetuximab. He achieved a radiographic response, biomarker decline, hematologic recovery, and improvement in ECOG performance status from 3 to 0, with benefit lasting approximately 6 months. At progression, circulating tumor DNA revealed persistence of RAF1 S257L at high allele fraction with RAF1 amplification, together with newly acquired EGFR ectodomain mutations, KRAS alterations, and a MAP2K1 alteration—a polyclonal pattern of convergent MAPK/EGFR reactivation. This case illustrates how a molecular tumor board can translate a rare driver into a rational, individualized regimen and how serial liquid biopsy informs resistance and next steps.Keywords
This publication has 9 references indexed in Scilit:
- Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201Journal of Clinical Oncology, 2025
- Avutometinib plus cetuximab after chemotherapy in patients with KRAS -mutated metastatic colorectal cancer: Results of phase 1 dose escalation.Journal of Clinical Oncology, 2025
- RAF1 contributes to cell proliferation and STAT3 activation in colorectal cancer independently of microsatellite and KRAS statusOncogene, 2023
- The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancerGenes, Chromosomes and Cancer, 2019
- Inhibition of RAF1 kinase activity restores apicobasal polarity and impairs tumour growth in human colorectal cancerGut, 2016
- Gaucher disease: haematological presentations and complicationsBritish Journal of Haematology, 2014
- Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancerNature, 2012
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with VemurafenibCancer Discovery, 2012
- Molecular and clinical analysis ofRAF1in Noonan syndrome and related disorders: dephosphorylation of serine 259 as the essential mechanism for mutant activationHuman Mutation, 2010